

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

**RESIGNATION OF ASSISTANT COMPANY SECRETARY
AND
CHANGE OF ALTERNATE TO AUTHORISED REPRESENTATIVES**

The Board announces that Mr. Yang is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules. The Board further announces that Ms. Cheng has tendered her resignation as an assistant company secretary and alternate to authorised representatives of the Company with effect from 3 July 2017. Following the resignation of Ms. Cheng, Mr. Yang will continue act as the company secretary of the Company and Ms. Yuan, securities assistant of the Company, has been appointed as an alternate to authorised representatives of the Company in place of Ms. Cheng with effect from 3 July 2017.

Reference is made to the announcement of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) dated 24 June 2014 (the “**Previous Announcement**”) in relation to the appointment of Mr. Yang Liang (“**Mr. Yang**”) as the company secretary and authorised representative of the Company with effect from 24 June 2014. As stated in the Previous Announcement, the Company had applied for and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) had granted the Company a waiver from strict compliance with Rule 3.28 and Rule 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) for a period of three years commencing from 24 June 2014 (the “**Waiver Period**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that after the end of the Waiver Period, the Stock Exchange had confirmed on 27 June 2017 that Mr. Yang is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules. The Board further announces that Ms. Cheng Pik Yuk (“**Ms. Cheng**”) has tendered her resignation as an assistant company secretary and alternate to authorised representatives of

the Company with effect from 3 July 2017. Following the resignation of Ms. Cheng, Mr. Yang will continue to act as the company secretary of the Company and Ms. Yuan Ailing (“**Ms. Yuan**”), securities assistant of the Company, has been appointed as an alternate to authorised representatives of the Company in place of Ms. Cheng with effect from 3 July 2017.

Ms. Cheng has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Company would like to express its sincere gratitude to Ms. Cheng for her significant contribution to the Company during her tenure of office and extend its welcome to Ms. Yuan on her new appointment.

By order of the Board
Livzon Pharmaceutical Group Inc. *
麗珠醫藥集團股份有限公司
Yang Liang
Company Secretary

Zhuhai, China

3 July 2017

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Xu Guoxiang (Vice President); the Non-executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*